Hemant P. Joshi

     E-mail: joshi029@umn.edu

     Year Entered: 2004

     Degrees Received:
     Dartmouth College
     Biophysical Chemsitry
     B.A., 2004

     University of Minnesota
     Pharmacology Graduate Program
     Ph.D., 2011

Honors and Awards:
-Graduated Cum Laude and as a Presidential Scholar from Dartmouth College in 2004

Thesis Advisor : Sundaram Ramakrishnan, Ph.D.

Thesis Research:  
One of the most promising emerging cancer therapies involves attacking tumor vasculature to control and diminish cancer growth. Anti-angiogenic molecules such as endostatin and angiostatin have recently been used with success in this regard. Our lab uses a virus-mediated approach to deliver endostatin and other anti-angiogenic factors to areas of tumor infiltration. In particular, my project aims to use adeno-associated virus (AAV) to transfect cells in and around tumor sites to deliver a genetic sequence encoding a mutant form of endostatin that has been shown to be more effective at inhibiting blood vessel growth than the wild-type form. The mutant endostatin gene is tagged with a secretory sequence that promotes relocation into extracellular areas where the protein can exact its anti-angiogenic effects on tumor vasculature. We hope that this novel therapy can be combined with existing strategies such as chemo- and radio-therapies to create a powerful combination treatment for cancer patients.

Publications (pubmed):

Ghosh G, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D, Chandrashekhar YS, Hall JL, Roy S, Zeng Y, Ramakrishnan S. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-α isoforms and promotes angiogenesis. J Clin Invest. 2010 Nov 1;120(11):4141-54. doi: 10.1172/JCI42980.

Subramanian IV, Devineni S, Ghebre R, Ghosh G, Joshi HP, Jing Y, Truskinovsky AM, Ramakrishnan S. AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer. Gene Ther. 2011 Feb;18(2):145-54.